Investors should monitor upcoming Phase 2b data readouts as key catalysts; positive results could validate KT-621 as a best-in-class oral therapy for Type 2 inflammation, supporting premium valuation ahead of pivotal trials.
Price Chart
Executive Summary
Kymera Therapeutics announced positive Phase 1b trial results for KT-621, an oral STAT6 degrader, showing deep target degradation and encouraging clinical activity in patients with moderate-to-severe atopic dermatitis. The data support further development in ongoing Phase 2b trials, with readouts expected by mid-2027 and late-2027.
Key Facts
- KT-621 demonstrated 94% median STAT6 degradation in skin and 98% in blood after 28 days of dosing.
- Robust biomarker reductions: 74% median TARC reduction, up to 73% Eotaxin-3, 56% IL-31, and 14% IgE.
- Clinical improvements: 63% mean EASI reduction, 29% achieved EASI-75, 19% reached vIGA-AD 0/1, 40% peak pruritus NRS reduction.
- KT-621 was well tolerated with a favorable safety profile.
- Phase 2b trials (BROADEN2 in AD, BREADTH in asthma) ongoing; data expected mid-2027 and late-2027.
Financial Impact
No direct financial impact reported; potential long-term value creation if Phase 2b trials confirm efficacy.
Risk Factors
- Phase 1b results may not be predictive of Phase 2b or Phase 3 outcomes.
- Competition from established biologics (e.g., dupilumab) and emerging oral agents in atopic dermatitis.
- Dilution risk from future capital raises to fund advancing clinical programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264183 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access